Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...

Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference.

Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ...

Novavax (NasdaqGS:NVAX) recently amended its collaboration agreement with Takeda, enhancing its revenue potential through a new upfront payment structure and future royalties. These developments, ...

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

Novavax (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement with Takeda (TAK).

Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®, a protein-based ...

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in ...

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...